论文部分内容阅读
对HBsAg阳性慢性肝病(HBsAg阳性CLD)患者给予抗病毒治疗可抑制病毒复制,对有些患者尚可改善其病情。然而只有病毒大量复制(即HBeAg阳性和DNA聚合酶阳性)的患者才适用此种治疗。本文旨在确定究竟有多少HBsAg阳性CLD患者适于抗病毒治疗。按Fogarty标准诊断为CLD的171例患者作为观察对象。所有患者均经腹腔镜作肝活检。HBsAg阳性CLD患者病毒复制标记:慢性迁延性肝炎(32例):HBeAg阳性34.3%,DNA聚合酶(DNAP)
Antiviral treatment of patients with HBsAg-positive chronic liver disease (HBsAg-positive CLD) inhibits viral replication and may improve the condition in some patients. However, this treatment is only available to patients who have a high viral replication (ie, HBeAg positive and DNA polymerase positive). This article aims to determine exactly how many patients with HBsAg-positive CLD are suitable for antiviral therapy. 171 patients were diagnosed as CLD according to the Fogarty standard. All patients underwent laparoscopic liver biopsy. Virus replication markers in patients with HBsAg-positive CLD: chronic persistent hepatitis (32 cases): HBeAg positive 34.3%, DNA polymerase (DNAP)